LBF20303PG05: Difference between revisions
No edit summary |
No edit summary |
(No difference)
|
Revision as of 14:00, 19 February 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1705 |
LipidMaps | LMFA03010142 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20303PG05 |
Prostaglandin D3 | |
---|---|
Structural Information | |
9α,15S-dihydroxy-11-oxo-prosta-5Z,13E,17Z-trien-1-oic acid | |
| |
Formula | C20H30O5 |
Exact Mass | 350.20932407 |
Average Mass | 350.4492 |
SMILES | C(=CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)C(C[C@@H]1O)=O)CC |
Physicochemical Information | |
PGD3 is produced by the metabolism of EPA via the cyclooxygenase pathway. Kulkarni_PS et al. | |
PGD3 has almost same ability to decrease systemic blood pressure in rats and to decrease intraocular pressure in rabbits. Bundy_GL et al. Goh_Y et al. Kulkarni_PS et al. However, it is 3 to 5 times more potent than PGD2 in the inhibition of ADP-induced human platelet aggregation. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|